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Abstract
Autoimmunity is a condition in which the host organizes an immune response against 
its own antigens. Rheumatoid arthritis (RA) is an autoimmune disease of unknown 
etiology, characterized by the presence of chronic inflammatory infiltrates, the devel-
opment of destructive arthropathy, bone erosion, and degradation of the articular car-
tilage and subchondral bone. There is currently no treatment that resolves the disease, 
only the use of palliatives, and not all patients respond to pharmacologic therapy. 
According to RA multifactorial origin, several in vivo models have been used to evalu-
ate its pathophysiology as well as to identify the usefulness of biomarkers to predict, 
to diagnose, or to evaluate the prognosis of the disease. This chapter focuses on the 
most common in vivo models used for the study of RA, including those related with 
genetic, immunological, hormonal, and environmental interactions. Similarly, the 
potential of these models to understand RA pathogenesis and to test preventive and 
therapeutic strategies of autoimmune disorder is also highlighted. In conclusion, of all 
the animal models discussed, the CIA model could be considered the most successful 
by generating arthritis using type II collagen and adjuvants and evaluating therapeutic 
compounds both intra-articularly and systemically.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provi ed the origi al work is properly cited.
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1. Introduction
Traditionally the immune system has been considered as a set of structures (molecules, cells, and 
specialized tissues) and biological processes responsible for the defense against aggression by a 
variety of infectious agents, chemicals, and tumor cells. One of the fundamental characteristics 
of the immune system is its ability to discriminate foreign antigens [1]. Autoimmunity is a multi-
factorial condition in which the host organizes an immune response against its own antigens [2]. 
Autoimmunity is associated with genetic, immunological, hormonal, and environmental factors, 
with it being classified as organ-specific and systemic, of which RA is one of the most representative.
RA has an incidence of 5 per 100,000 adults and occurs in 0.5–1% of the population in indus-
trialized countries [3]. The RA can manifest as pain, stiffness, swelling, and loss of mobility. 
There are different strategies for the study of RA, including experimental animal models that 
help elucidate different aspects of the disease, as well as evaluate compounds that can reduce 
the inflammation that triggers the disease. An ideal animal model for RA should reproduce as 
close as possible the complex pathogenesis and symptoms that underlie the disease, including 
the presence of chronic inflammatory infiltrates, the development of destructive arthropathy, 
bone erosion, and degradation of the articular cartilage and subchondral bone [4]. Current RA 
animal models are highly reproducible and of short duration, having similar patterns to those 
occurring in human disease although they present some differences, such as (1) faster progres-
sion of the disease, characterized by an acute inflammatory response and (2) rodents have a 
tendency to marked resorption and bone formation (especially of the periosteum/endosteum) 
in response to joint inflammation. The use of animal models has contributed significantly to 
the knowledge of processes and mediators that generate inflammation and bone and cartilage 
damage and, in this sense, can be used as an intermediary to provide knowledge and for the 
evaluation of therapeutic molecules to correct these disorders [5]. There are numerous thera-
peutic alternatives for RA; however, the duration of these therapies and the side effects associ-
ated with some of these drugs mean that until now, there is no effective therapy for this disease.
2. The human immune system and manifestations of RA
2.1. Primary and secondary lymphoid organs and defense mechanism
The immune system is responsible for protecting the human body from external and potentially 
pathogenic organisms. It is made up of a series of cells, tissues, and organs distributed widely 
throughout the body. From the point of view of its structural characteristics, there are organs 
such as the thymus, spleen, and lymph nodes and tubular structures such as the lymphatic 
vessels that are intercommunicated. If the functions performed are taken into account, they 
can be classified into primary and secondary lymphoid organs. The primary lymphoid organs 
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(thymus and bone marrow) produce T and B lymphocytes, while secondary lymphoid organs 
include lymph nodes (LNs), spleen, Peyer’s patches (PPs), and mucosal tissues, nasal-associated 
lymphoid tissue (NALT), adenoids, and tonsils, which also harbor perifollicular areas [6].
The immune system has two lines of defense, specific and nonspecific (adaptive and innate), 
which are responsible for keeping the body free from pathogens or, if present, can eliminate 
them as well as their residue [7, 8]. The innate, nonspecific antigen response destroys micro-
organisms and triggers an inflammatory process that blocks the spread of infection. If micro-
organisms get past this first barrier, antigen-specific adaptive immunity composed of T and B 
lymphocytes can produce antibodies and killer cells that destroy infected cells [9]. The innate 
immunity is constituted of external barriers such as mucous and skin; the inflammatory process; 
cells such as macrophages, natural killer (NK) cells, and phagocytic cells; and chemicals. In rela-
tion to adaptive immunity, this is generated only after exposure of inducing agents, and two 
distinct responses are generated, the cellular response, in which T lymphocytes are responsible 
for generating this reaction and the humoral response, carried out by B lymphocytes, which in 
turn are responsible for producing antibodies against the agents that cause damage [10].
2.2. Autoimmune disease as an imbalance in immunoregulation
Autoimmune diseases have been classified according to the organ and tissues affected by the 
impaired immune response. Nearly 80 autoimmune diseases have been reported to date, and 
a prevalence of 5–6% worldwide has been stated [11].
An autoimmune manifestation is triggered by antigens that are generated naturally in an 
individual, and most of the time, these autoimmune events are devoid of pathological charac-
ter. A large number of people worldwide have autoantibodies to different parts of the body, 
which are activated when a viral or pathogen infection is present. These diseases are usually 
the result of an imbalance of immunoregulation [12].
The process by which autoimmune disease is triggered follows different pathways including 
infection with viruses or bacteria, the use of drugs, the use of irritant chemicals, and environmen-
tal factors that damage health. The infection is capable of generating enzymatic changes which in 
turn alter cell membranes exposed to hidden antigens or may expose new antigenic sites [13]. Also 
the viral infection can induce new antigens that are released or expressed on its cell surface [14].
Among the first signs of autoimmune disease are pain, swelling, heat, and inflammation [15]. 
The affection of these diseases will depend on the target organ, since any part of the body, 
such as the eyes, heart, joints, or brain, can be attacked [16].
Aging and molecular haptens are also associated with the formation of new antigens or the 
appearance of those that are hidden; in the haptens a response is triggered both against them 
and the protein to which they bind [17]. Such antigens may be obtained from diet or gener-
ated from virus cross reactions with antigens that are present in the individual which force 
the immune system to react against them.
There are several theories which consider that these types of autoimmunity are due to the 
loss of tolerance of T lymphocytes or their inability to effectively suppress the reaction that is 
generated against their own antigens or harmless agents [18].
Animal Models of Rheumatoid Arthritis
http://dx.doi.org/10.5772/intechopen.72554
259
Autoimmunity is triggered when the response is persistent and leads to the development of 
uncontrolled cells that react aggressively against any component of the body [19]. These pro-
cesses require the entry of effector cells into the target organ, whereby there are changes in 
blood vessels due to the inflammatory substances that are released into the blood [20]. There are 
different associated factors that trigger an autoimmune disease such as those shown in Figure 1.
Recognition of the major histocompatibility complex (MHC) II by the T-lymphocyte receptor 
(TCR) will produce a clustering with other surface receptors that activate a signaling cascade, 
which in turn alters the T-lymphocyte transcriptional program. These events produce tissue 
destruction and loss of function of affected organs during the course of the autoimmune dis-
ease. There is evidence that CD4+ T cells are active in local inflammation and cell infiltration 
that result in inflammation [21].
2.3. Rheumatoid arthritis, its causes and prognosis
RA is a chronic inflammatory disease characterized by synovitis with a symmetrical distribu-
tion that causes severe joint destruction [22]. RA is a common autoimmune systemic inflam-
matory disease that affects approximately 1% of the worldwide population and its incidence is 
0.5–1% [3]. Cohort studies have shown that people with arthritis are 54% more likely to die than 
a healthy person, and there are data that indicate that this frequency is directly associated with 
the severity of the disease [23]. The process was reported in 1909 by Nichols and Richardson, 
and among the symptoms of RA are a prodromal period preceded by overt asthenia, gen-
eral malaise, diffuse myalgia, fever, and anorexia, weight loss, pain, stiffness, and swelling in 
affected joints [24].
RA initiates as an inflammation of synovial fluid, in which rheumatoid factor (RF), IgM and 
IgG, and anti-CCP antibodies are present in serum and joints. Complement is activated within 
the synovial fluid, with C3a and C5a being the most important components found [9]. The 
disease is perpetuated by the production of cytokines and the action of extracellular matrix 
metalloproteinases (MMP) [25].
Figure 1. Factors associated with the development of autoimmunity. There are several important factors that are 
considered the trigger of an autoimmune disease, since the true etiology is not currently known. These include hormonal, 
immunological, environmental, or genetic factors (susceptibility).
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After the onset of the disease, the synovial membrane of patients with RA, which is generally 
hypocellular, becomes hyperplastic, containing a large number of cells, such as polymorpho-
nuclear leukocytes surrounding immune complexes and complement molecules [26].
Chronic inflammation in hypertrophic synovium is maintained by activated cell groups such 
as synovial fibroblasts and macrophages, as well as an area containing a clear cell infiltrate: 
mast cells, CD4+ and CD8+ T lymphocytes, NK cells, B lymphocytes, and plasma cells (the 
latter produce RF against altered IgGs), along with invasive mesenchymal cells. This accumu-
lation of complexes and cells forms what is called pannus [26].
Once the presence of inflammatory arthritis is recognized, a preliminary diagnosis is made; 
other diagnoses of arthritis (lupus, psoriatic arthritis, spondyloarthritis, among others) are ruled 
out. Finally, the risk of developing persistent and/or erosive arthritis is assessed. Patients with 
early RA develop symmetrical polyarthritis, and its appearance is associated with the presence 
of positive rheumatoid factor (RF) and/or anti-citrullinated (anti-CCP) antibodies. RF corre-
sponds to antibodies that are directed against immunoglobulins IgG, IgM, and IgA and are usu-
ally present in 80% of the patients who suffer this disease [27]. In RA, the inflammatory process 
is mediated primarily by the action of pro-inflammatory cytokines. In addition to enhancing 
the activity of IL-1 and TNF-α, IL-17 has a direct effect on the evolution of the disease, since it 
stimulates osteoclast differentiation and promotes the destruction of the cartilage and bone [28].
Until a few years ago, Th1 cells were considered to be the main cause of tissue damage in 
autoimmune diseases, but Th17 is currently considered to be the major inducer of autoim-
mune disease. It migrates more rapidly than Th1 to the areas of lesion. Once there, it stimu-
lates the inflammatory response and is able to recruit other complementary cells, including 
Th1, which is necessarily associated with Th17 for inflammation and tissue destruction [29].
The onset of RA involves certain components such as T cells (CD4+), monocytes, fibroblasts, 
B cells, dendritic cells, mast cells, and neutrophils [30]. The synovium of patients with RA 
usually presents a certain red coloration due to the strong inflammation that is present. 
Chemokines are usually very important in the pathogenesis of the disease, being the most 
representative of the CXC family which is a strong promoter of angiogenesis [31].
Cytokines are implicated in the pathogenesis of RA, which triggers and perpetuates autoim-
munity, maintaining chronic inflammatory synovitis and directing the destruction of con-
nective tissue. Therefore, they integrate the regulatory immune events and destruction of the 
tissues that are observed in the clinical progression of RA. Cytokines that play an important 
pro-inflammatory role in arthritis are TNFα, IL-1β, IL-6, and IL-17 [32].
3. In vivo models for RA
RA is a cosmopolitan disease that affects 60 million people, making it a big problem for the 
health sector [33]. The etiology and pathophysiology of RA remain poorly understood, but 
it is generally accepted that genetic, immunological, hormonal, and environmental factors 
could lead to chronic inflammatory infiltrates, the development of destructive arthropathy, 
and the manifestation of clinical symptoms [34].
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Since 1806, RA has been associated with a certain degree of inheritance; its relationship with 
genetic and environmental components has not been neglected in greater proportion [35]. 
There are different experimental models that generate basic knowledge of the pathophysiol-
ogy of RA for the development of diagnostic kits through the discovery of biological markers. 
These are grouped in genetic, immunological, hormonal and environmental characteristics; 
that is, these factors are always associated with most autoimmune diseases.
3.1. Genetic models
The first RA-associated gene appeared in 1978 with the elucidation of HLA association with 
the disease. Nowadays, it is a clear complex of predisposition to suffer RA [36].
The first set of studies aimed at demonstrating the genetic susceptibility to RA was performed 
in twins, in which the environment and the genome were similar. This led to the hypothesis 
that 60% of the changes are attributable to genetic components. One of the best strategies has 
been to link polymorphisms with RA; despite these efforts, only HLA and PTPN22 factors 
have been linked with accurate results, hence the importance of genetically modified animal 
models [3, 37].
The collagen-induced arthritis (CIA) model was developed through the induction of type II 
collagen although the usefulness of other types of collagen has been demonstrated [38]. This 
model has become the most effective genetic biomarker. Among the targets that have been 
evaluated are immunoglobulin-producing B cells which attack type II collagen. Additionally, 
TCR transgenic mice in which the development of arthritis has been generated by immuno-
globulins have also been evaluated [39, 40].
The way in which the transgenic mice model is developed is by injecting a construct that 
weighs an expression promoter, the gene or molecule of interest, and, commonly, a reporter 
gene, which will facilitate the exact location of the construction generated by immunofluores-
cence techniques. Once this construction is obtained, it is introduced into a pronucleus of a 
fertilized egg. The mouse that will be obtained will be able to express the gene of interest and 
transmit it to its descendants [41].
The therapeutic targets evaluated in CIA models or transgenic mice with adjuvants (from 
DBA/1 strain) are genes that code for T lymphocytes, within which the generation of a polymor-
phism has been associated with the development of RA. Finally, CMH, whose association with 
RA was reported in 1978, has been assigned to different loci such as HLA-DQ and HLA-DR, as 
well as to the H-2q region of HCM, demonstrating involvement in animal models with trans-
genic mice. Despite efforts to detect altered genes in this complex, to date, the exact pathway 
in which the pathogenesis is produced and the precise effect of this complex on the disease are 
unknown [42]. Table 1 summarizes the animal models used for the genetic model of RA.
3.2. Immunological models
Among the immunological factors, commonly considered biomarkers are cytokines, chemo-
kines, immune response cells, and adhesion molecules.
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Cytokines often provide valuable information within the role of soluble factors that develop 
in RA. IL-1 β, TNF-α, IL-6, IL-15, and IL-18 are the most documented cytokines that play a 
regulatory role in RA, depending on the immune response or inflammatory processes.
Model Inbred strain and 
mechanism
Genotypic 
characteristics
Limitation Advantage Reference
IL-6R The genetic background 
is with strain C57BL 
/ 6 and the model is 
generated due to a 
mutation generated in the 
amino acid tyrosine in the 
IL-6 receptor.
gp130F759/F759 A high frequency of 
B cells is generated, 
which could result in an 
increase in the humoral 
response.
Mutation in 
GP130 enhances 
IL-6 expression.
[4, 43, 44]
IL-1Ra The strain used is C57BL 
/ 6J and said mice are 
deficient in the gene that 
enconding for the IL-1Ra 
receptor antagonist.
B6.129S-
IL1rntm1Dih/J
Fail to respond to IL-1 
and exhibit an altered 
immune response to 
many different target 
proteins.
Exhibit altered 
inflammatory 
responses.
[4, 43, 45]
K/BxN For this model, the strains 
of NOD and C57BL/6 
are used, in which 
autoimmunity against the 
GPI is generated after its 
crossing.
B6.TCR.
Cα−/−.H-2bxg7
-Number of experimental 
mice obtained from very 
small crosses.
-Controls may generate 
arthritis
-Additional care due to 
complexity of the model.
-Obtain control 
mice, arthritic 
and experimental 
at the same time.
-Development 
of early 
arthritis and RF 
production.
[4, 43, 46, 
47]
SKG A mutation occurs in 
the SH2 region of the 
ZAP 70 protein, which is 
the result of an error in 
the selection of T cells, 
the mouse model is the 
BALB / c
ZAP-70W163C -Do not develop 
lymphadenopathy or 
lupus-like diseases.
-Arthritis is significantly 
reduced when the mice 
are rendered TNF-α, IL-1 
or IL-6 deficient.
-Develop RF 
and anti-CCP 
antibody.
-Mutation in the 
SH2 domain of 
Zap 70.
-Spontaneous 
arthritis.
[4, 43, 48]
TNF-α-
transgenic
The animal strain used 
is C57BL / 6 in which an 
overexpression of the 
human TNF-α gene is 
generated
Tg197 Have impaired fertility 
and therefore it is 
very difficult to obtain 
offspring from this 
model.
-Increased TNF-α 
production.
-May lead to 
the discovery of 
novel treatment 
and prevention 
alternatives.
-Develops 
an erosive 
polyarthritis.
[4, 43, 49, 
50]
CCP, cyclic citrullinated peptide; RF, rheumatoid factor; TNF, tumor necrosis factor; IL, interleukin; α, alpha; SKG, 
Sakaguchi; BL, black; ZAP 70, zeta-chain associated protein 70; SH
2
, Src homology 2; GP130, glycoprotein 130; R, 
receptor; Ra, receptor antagonist; NOD, nonobese diabetic; TCR, T cell receptor.
Table 1. Genetic models for RA.
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The mice strains that are used for evaluation of some cytokines or regions of the TCR are 
knockout mice or transgenic mice, which have a deficiency of the molecule to be stud-
ied. Typically, these strains develop the CIA model more easily than other strains such as 
C57BL/6 [51].
In addition, different therapeutic targets such as chemokines, signaling molecules, and cel-
lular trafficking can be evaluated in arthritis models like collagen-induced arthritis (CIA), 
streptococcal cell wall (SCW), adjuvant-induced arthritis (AIA), and models in chemokine-
deficient knockout mice. On the other hand, immune response cells (NK, monocytes, etc.) 
are evaluated in K/BxN mice with CIA, which must be pre-stimulated with LPS to inhibit Fc 
receptors. Adhesion molecules, whose function resides in leukocyte trafficking, have been 
referred to be evaluated in SCW models with BALB/c mice and among the markers found are 
P-selectin, ICAM-1, and VCAM-1 [52].
For this model, K/BxN mice, which will jointly express the cell receptor T and the CMH II 
allele, are usually used. These mice typically develop no problem with a severe form of arthri-
tis, when they are inoculated with serum antibodies due to high levels of GPI. Two mice are 
required to generate the model: one from the C57BL/6 strain that has the KRN and NOD/Lt 
transgene carrying the CMH II allele [53].
3.3. Environmental models
One marker that has been associated with RA is a low socioeconomic level, from which 
unhealthy diets are derived. It has recently been found that the consumption of certain vitamins 
and minerals from healthy food provides protection and reduces the effects of RA in patients 
[54, 55].
In animal models, the first link in which the association of the environment in arthritis was 
observed was when the HLA-B27 complex was evaluated in transgenic rats with spondyloar-
thritis. The rats did not develop the disease, so it was deduced that normal intestinal flora in B27 
plays an important role [56]. Among the main environmental links with RA are smoking, the 
presence of infections, antibodies to rheumatoid factor, and anti-cyclic citrullinated peptides [57].
Cigarette smoke is strongly associated with RA, and during a study in 2011 in which mice of 
the DBA/1 J strain were in contact with condensed smoke, an increase in the induction of RA 
mediated in the CIA model. This strongly suggests that smoking may be an etiologic cause of 
this pathology [58].
4. Implication of hormones in animal models
Sex hormones are linked to RA because they function normally as inhibitors or suppressors 
of the immune response. Over the last few years, it has been speculated that the appearance 
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Animal model Characteristics Species Limitations
Streptococcal cell wall arthritis Peptidoglycans in the cell walls of 
bacteria (Streptococcus sp., Lactobacillus 
sp.) are responsible for inducing the 
model. Biphasic arthritis is generated, 
and it persists for several months. The 
model is generated in Lewis rats
Rat The most important 
limitation is that the 
arthritis that is generated 
is monoarticular, and 
because the inflammation 
is generated by injecting 
intra-articularly, the systemic 
effects cannot be effectively 
evaluated
Passive transfer of CIA 
antibodies
The induction is performed by 
injecting type II collagen. The 
generation of specific antibodies for 
type II collagen is well characterized. 
Mice used are B-cell deficient and 
resistant to developing CIA
Mouse It does not generate B- or 
T-cell responses, which 
are important factors to 
evaluate in RA despite 
having macrophages and 
polymorphonuclear cell 
infiltrates
Collagen-induced arthritis This model is inducible in susceptible 
mice and rats; it is the gold standard 
and causes polyarthritis. Animals 
are inoculated with collagen II and 
coadjuvant; a re-restriction of MHC 
II is generated. The most commonly 
used strain of mice is DBA 1/J
Rat, mouse Prior experience is required 
to perform the injection 
of the agents to evaluate 
intra-articularly. Arthritis 
characterized by polyarthritic 
does not meet all the 
characteristics, and results 
generated are variable. The 
arthritis that is triggered is 
acute
Immune complex-induced 
arthritis
Is generated for passive transfer of 
anti-isozyme antibodies in mice, 
which are injected into the knee with 
poly-L-lysine-lysozyme
Rat, mouse The model does not comply 
with endogenous factors 
that are generated, and it 
is very difficult to resemble 
certain models such as 
CIA. Reactivity is generated 
by the presence of type II 
collagen and increases the 
production of factors that 
trigger inflammation
Spontaneous arthritis in 
knockout or transgenic mice
Mutations generated in the model 
are only generated in mice 4–5 weeks 
of age. Arthritis is mild and can 
be induced by serum transfer and 
induces changes in the MHC
Mouse These models require specific 
environmental stimulants, 
which are very sensitive to 
the changes; therefore they 
are usually models with 
considerably high costs. 
Another limitation is that 
antibodies to anti-glucose-
6-phosphate isomerase are 
generated that mostly cause 
pathogenic effects
RA, rheumatoid arthritis; CIA, collagen-induced arthritis; MHC, major histocompatibility complex.
Table 2. In vivo models for the study of RA.
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of polymorphisms in genes encoding testosterone, progesterone, and androgens is what trig-
ger an imbalance in the hormone complex with immune system and thus be associated with 
RA [59].
A higher prevalence of arthritis is present in females, but in murine models, it has been shown 
that for CIA and antibody-induced arthritis models, male mice and rats (CIA only) exhibit a 
higher prevalence. Castration of male mice produces a high prevalence of arthritis in the SCW 
model [60].
Another hormone that can also be a marker is cortisol secreted during periods of stress. In 
mice it has been shown to reduce the sensitivity to be induced in the CIA model; therefore, 
it usually confers some protection [61]. Tables 2 and 3 summarize the in vivo models for the 
study of RA and the information of the genetic, immunological, and environmental animal 
models used in RA, respectively.
Characteristic Model
Genetic Immunological Environmental
Model genetic 
background
Transgenic mice deficient in 
a specific gene to evaluate the 
effect of this in the murine 
model.
Arthritis is induced by transfer 
of antibodies in the serum to 
susceptible mice, transgenic mice 
and induced by adjuvants
When in contact with external 
pollutants, in the animal model, 
the induction of RA in the CIA 
model increases.
Advantages -A specific genetic model 
allows studying how the 
disease is developed during 
prolonged periods and with 
possibility of repetition.
-It allows knowing the 
functioning of the genes 
involved in RA.
Generates knowledge about 
several inflammation-related 
molecules and their implications 
in its signaling pathways.
This model gives the facility to 
know how the environmental 
influences the intestinal flora and 
the development of RA.
Year of 
development
In 1991 the first genetic model 
was developed, which was of 
mice that overexpressed the 
human TNF-α gene
The model of adjuvant arthritis 
was the first to be described in 
1956
The main environmental risk 
factor for the development of 
arthritis is smoking and the first 
murine model of this factor was 
described in 1992.
Limitation - Place of indeterminate 
integration.
- Expensive model.
-Variable gene expression
- Evaluation of a single gene at 
a time.
- It is generated in inducible 
models and less in transgenic 
mice
- There are very few genes or 
alterations that are evaluated in 
this model for RA so it is almost 
obsolete.
Phenotypic 
expression
Transgenic mice C57BL/6, K/BxN DBA 1/J
Reference [42, 62] [51, 62] [58, 63, 64]
RA, rheumatoid arthritis; CIA, collagen induced arthritis.
Table 3. Comparison of animal models for the study of RA.
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5. Therapeutic strategies
Over the years, different RA therapies have been developed; one of the most representatives 
is TNF blockers, which, although effective, generate some notable side effects. The impor-
tance of animal models serves to generate the knowledge and evaluation of new therapies 
[52]. All these models are intended to induce inflammation and subsequent destruction of 
one or more peripheral joints in different animal species, with rodent species, such as mice 
and rats, being the most frequently used. The most common administration routes for evalu-
ation of compounds in murine RA models are two, as shown in Figure 2. The most common 
administration route used for molecules including viral vectors such as lentivirus, retrovirus, 
and adeno-associated virus is intra-articular, which consists of administering a vector that 
contains a gene with regulatory effects on some mechanism of RA in the joint of the ani-
mal model being evaluated. Recently, murine models have been evaluated in which the viral 
vector is administered systemically (intravenously), and these have been able to reduce the 
 inflammation generated by the disease as well as other clinical symptoms, without decreasing 
the effectiveness associated with the route of administration [52].
Some of the therapeutical goals of drugs, irrespective of their route of administration, include 
regularizing cytokine levels, since there is an overproduction of these, adjusting the expression 
levels of transcriptional products that cause inflammation and bone degradation, and decreas-
ing chemokines and adhesion molecules, all of which are determinants of RA pathogenesis [52].
The models most used for the evaluation of exogenous substances that help reduce the dis-
ease are varied [65]; besides they depend on the animal model, as thus illustrated.
Figure 2. Animal models in RA. The models that are currently used for the generation of RA in mice and rats are 
varied and depend on the purpose. This can be generated by adjuvants with susceptible animals or spontaneously with 
genetically modified animals. There are several routes of administration which depend on the vehicle to be administered; 
for gene therapy the most used are the intra-articular and systemic routes.
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5.1. Rat models
5.1.1. Streptococcal cell wall (SCW) arthritis
The SCW arthritis rat model is an experimentally induced inflammatory model with many 
features which resembles RA in humans. This model is used for studies of pathogenesis, 
therapy, and obtaining genetic knowledge in the acute and chronic phases of inflammation. 
Arthritis is induced in strains of rats that are susceptible (Lewis rat strain) and is performed 
by intraperitoneal injection of peptidoglycan polysaccharide polymers, which are obtained 
from the cell wall of Streptococcus pyogenes group A, D58 strain. This model representatively 
generates the severity of the arthritis and also generates granulomas in the liver, spleen, and 
peritoneum, granulomatous enterocolitis, and uveitis [66].
Commonly the streptococcal walls are formed by peptidoglycans (PG) bound to specific poly-
saccharides. These peptidoglycans have the function of triggering chronic arthritis, followed 
by a systemic response. Once these PGs are deposited in aqueous solution, three events may 
occur, which may be deposited in articular tissues. These may last a long time that stimulate 
the macrophages and pro-inflammatory mechanisms of T-cell activation [67].
The SWC model with Lewis rats (endogenous strain that is highly susceptible) is initiated 
after injection of the PGs in aqueous form. Once the inoculation takes place, it is necessary to 
observe the animals daily to verify the development of arthritis during the first 6 days, after 
this they can be checked every 2–3 days for at least 6–8 weeks. The acute response of this 
model develops from the first 48 hours to the next 10–21 days; finally, the chronic phase is 
triggered, which persists for several months in the animal model [67].
The conventional way of generating the model is using a systemic approach, which is obtained 
by intraperitoneal injection. But there are other alternatives that have been used in later years, 
such as injection of the cell wall intra-articularly. Strategic application will cause local inflam-
mation with edema in 24 hours and after 3 weeks; the inflammation will be very little notice-
able but will be accompanied by synovial infiltration of monocytes and remnant lymphocytes. 
The presence and importance of Th1 cells in the generation of arthritis for this inflammation 
model have been strongly suggested [68]. A single intraperitoneal administration of the cell 
wall is sufficient to generate arthritis and cause remission, although early experiments sug-
gest that systemic administration was performed [69]. Among the main therapeutic targets to 
be evaluated in this model are direct components of the immune system such as cytokines. 
There are different studies in which inhibiting the IL-37 and P2X7 receptor, regulating the 
function of IL-10, and decreasing IL-21 production will produce resistance to joint inflamma-
tion when presented with this SCW model [70–72].
5.2. Mouse model
5.2.1. Passive transfer of CIA antibodies
The gold standard animal model for the study of RA is arthritis induced by collagen (CIA). The 
induction is performed by injecting type II collagen, which is the most predominant constituent 
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protein of the joint cartilage, and its induction with native collagen and adjuvants produces polyar-
thritis of a cross-immune response to the homologous collagen. The susceptibility of CIA is linked 
to the expression of certain complexes such as MHC II, which plays a primordial role in T cells [73].
The generation of antibodies specific for type II collagen is highly characterized. Mice used 
are B-cell deficient and resistant to developing CIA. The antibodies were shown to induce CIA 
in the DBA1/J mice strain although the arthritis generated is very mild [74].
For the generation of this AR model, it is necessary to obtain anti-collagen type II antibodies, 
which are obtained from a CIA model. These antibodies can be extracted from different bio-
logical matrices such as serum.
These antibodies are important for the generation of CIA pathogenesis. This transfer shows that 
arthritis is identical in mice with restriction of T cells. Several studies confirm that the develop-
ment of the model depends on the joint response of B and T cells toward anti-CII antibodies [75].
The importance of knowing RF in RA is not well understood. It is believed to serve in the 
formation of immune complexes and in the formation of the complement system, which in 
turn attracts neutrophils to the site of inflammation [76]. The information is unclear to date, 
and arthritis is also believed to be induced by the binding of citrullinated peptide epitopes or 
by cross-reactivity [77].
This model is discussed in DBA1/J type mice, and since it is generated from a serum with 
antibodies in a CIA model, its targets are generally the same as IL-1β and TNF-α, although 
other therapies have also been discussed and approved, such as the inhibition of CTLA41g-
stimulated T cells and the decrease in B cells with anti-CD20 [78].
5.2.2. Collagen-induced arthritis
CIA is an autoimmune disease that is generated in rodents that are usually genetically predis-
posed to present features very similar to arthritis, with these being immunized with type II 
collagen emulsified with complete Freund’s adjuvant [34]. CIA in mice exhibits a restriction to 
MHC II in animals expressing H-2q and H-2r molecules [79]. Trentham et al. (1980), described 
the administration of type II collagen from chicken, emulsified in complete Freund’s adjuvant 
(CFA) is capable of producing rat arthritis [80]. It was later described that this disease can also 
be induced in mice [81].
This experimental model of arthritis was designed and described primarily in rats, but cur-
rently a mouse strain with genetic predisposition to arthritis, strain DBA/1, is used [11]. Due 
to its restriction to MHC II, it is obvious that T lymphocytes play a prominent role in the 
autoimmune response, both in the production and regulation of pro-inflammatory cytokines 
and in the modulation of the B-cell response [79]. Activated T lymphocytes also activate mac-
rophages to produce pro-inflammatory cytokines, TNFα, IL-1, and IL-6, among others, induc-
ing the expression of chemokines and adhesion molecules with the consequent infiltration of 
polymorphonuclear cells, MN and formation of pannus.
Histologically, the CIA presents intense synovitis that correlates with the development of the 
disease. About 5 weeks after application of type II collagen, the animals develop a polyarthritis 
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similar to RA that occurs in humans. In general, there is fibrosis and ankylosis of the involved 
joints, and among the histological alterations, erosion of the subchondral bone and formation 
of pannus can be observed, also autoantibody formation.
All these immunopathological processes of CIA involve a response of T and B lymphocytes. 
The administration of type II collagen induces a strong activation of cooperating T lympho-
cytes, which stimulate B lymphocytes to produce antibodies against this protein, and later, 
a series of antibodies that will interact with cartilage constitutive proteins also activate the 
complement system. In the serum of arthritic animals, antibodies to different proteins have 
been detected, in addition to type II collagen [82].
The first antigenic determinants of type II collagen, in the case of DBA 1 mice, have been 
identified with the H-2q haplotype; the antigenic determinant is between amino acids (aa) 257 
and 270 of the protein and in mice with the haplotype H-2r; it is between aa 442 and 456 [83].
Pro-inflammatory cytokines induce synovial cells such as chondrocytes, fibroblasts, and 
osteoclasts to produce MMPs and other effector molecules, all of which are responsible for 
cartilage degradation, bone erosion, and fibrosis [84].
B cells also play a key role in the development of CIA. It has been shown that the trans-
fer of immune serum from arthritic mice to healthy mice induces severe inflammation, and 
although the antibody is no longer detected, the inflammatory response persists. This indicates 
that the humoral response is capable of triggering more factors that have an important role in 
establishing the autoimmune response in this model [77].
For the CIA model in rats, the therapeutic agents that have been evaluated are methotrex-
ate and corticosteroids, and for biological targets, it is most common to evaluate the soluble 
receptor of TNF and IL-1, which have had effective results in decreasing the inflammation 
generated in the model [85].
CIA model but with mice which is currently the most commonly used with the DBA1/J strain 
because it has been shown that IL-1β boosts inflammation and perpetuates TNF-α, which have 
become the main therapeutic targets. Analogous collagen system peptides are currently evalu-
ated for good results by reducing the symptoms of the disease in the murine model [86, 87].
The main route of administration for evaluation of therapeutic compounds, used for this model, 
is intra-articular; despite being the most used, it has caused controversy in its applicability 
when used in patients. Therefore, in recent years, efforts have been made to replace it by other 
means such as the system, which, despite being used recently, has shown favorable results.
5.2.3. Immune complex-induced arthritis (IC)
There are certain important events in RA as the formation of immunocomplexes. These immu-
nocomplexes have been found in the synovium and joint cartilage of patients with RA [88]. 
The appearance of such complexes has been associated with the severity of the disease.
The most commonly used experimental models of RA, the antigen-induced arthritis, and the 
adjuvant-induced arthritis exhibit close resemblance to the pathophysiology of RA. However, 
they do not allow a precise investigation of the isolated contribution of IC to the development 
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of arthritis. In the case of articular lesions, it is important to note that there is no evidence of 
a significant increase in the prevalence of this type of disease on IC formation although the 
recruitment and activation of these cells in IC-induced lesions are considered essential to the 
full-blown development of the reaction [89].
This model has the advantage that its mechanism of action or effector molecules are generated 
in a simple way and knowledge of the pathogenesis of the disease is obtained quickly. Among 
the associated molecules are cytokines IL-1 and TNF-α, essential for the development of the 
disease, as well as macrophages, neutrophils, and mast cells [90, 91].
To generate the induction of RA, FcR, present in mast cells, neutrophils, and macrophages 
are very important. Activation of the complement pathway, mainly the C5a fragment, which 
functions as a chemoattractant factor, is also necessary [92, 93]. Also, innate components of the 
immune system often play an important role in the development of the CIA model. One exam-
ple is the specificity of the K/BxN model, despite the omnipresence of autoantigen GPI [94].
In this model, the cationic retention principle is used in the passive transfer of anti-lysozyme 
antibodies in mice, which are injected into the knee with poly-L-lysine-lysozyme. This com-
pound is large enough to be retained in the joints for a prolonged time and contributes to the 
joint destruction and chronicity of the disease produced by the model. The models with DBA/1 
mice show a strong dependence on IL-1, and TNF blockade is usually very ineffective [95].
In this model, immunocomplexes will generate arthritis-like inflammation, which can be trig-
gered in mice and rats (although in a lesser proportion). It is known that complement factors 
are usually a therapeutic target in this model and have recently added neutrophils, FcRy, and 
opsonic components which play a key role in RA inflammation [96].
5.2.4. Spontaneous arthritis in knockout or transgenic mice
Mice that are genetically modified will have various uses, such as the removal or introduction 
of genes for some receptor, cytokines, or other factors that help trigger immune mechanisms 
in the etiology of RA. Sometimes, spontaneous inflammation occurs, resulting in arthritis or 
another inflammatory disorder [52].
These models are much discussed at present, due to their ability to generate the disease, with-
out the need to inoculate the animal with adjuvants, antibodies, or some external agent as in 
the CIA, SWC, and AIA models.
The K/BxN mouse (transgenic KRN T-cell receptor mouse on the background C57BL/6 x NOD) 
spontaneously develops chronic and progressive inflammation [97]. Clinically visible joint 
inflammation is observed from the third week of disease onset and thereafter evolves into a 
chronic and severe type of problem. T cells and B cells generate autoantibodies that promote 
the perpetuation of disease and joint destruction [98]. In addition to T-cell involvement, B cells 
secrete autoantibodies that promote joint destruction. Like arthritis with immunocomplexes or 
passive antibody transfer, and similarly to the CIA model, arthritis can be induced by serum 
transfer and induces changes in the MHC. Arthritis is mild and nondurable and requires per-
sistence in the injection of serum with anti-CII antibodies. The fragment of Fc immunoglobu-
lins plays an important factor in this model. The K/BxN model is thus an important tool to 
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study the role of antibodies in the development of RA [66]. This model alone demonstrates 
that a specific molecule or antibody is not required to generate arthritis. The receptor of the T 
cells of the KRN strain recognizes the GPI and, on the other hand, the MHC [99]. This immune 
recognition of G6PI gives rise to autoantibodies to the isomerase which, when purified, can 
transfer disease. The relevance of this reactivity to the etiology of RA is unclear. Recognition of 
G6PI is first obtained by antibodies, and subsequently these can be transferred, although the 
relevancy of this discovery does not really generate knowledge toward RA.
The transgenic T-cell receptor of the krn strain was originally generated to recognize a bovine-
type antigen; its discovery was totally serendipity. Different authors have performed different 
series of studies to define the mechanism of action, the effector phases, as well as the evalua-
tion of cells involved in this animal model of RA [99].
On the other hand, immunization with G6PI induces an inflammatory arthritis that is depen-
dent on T cells in mice that have not been studied, generating clues about the knowledge and 
use of such a model [100].
In this model, arthritis is produced by transfer of serum antibodies from a previous arthritis 
model; mice are genetically modified to develop RA when it is induced. The targets in this 
model are cytokines and chemokines. The absence of these molecules is analyzed to verify if 
they generate protection or induction of RA and additional information such as the signaling 
pathway that it alters. The TRANCE/RANKL factor was one of the most used for evaluation 
of the NF-kB pathway with TNF [101]. The phenotypic characteristics of the major animal 
models are shown in Figure 3.
Figure 3. Phenotypic characteristics of animal models. There are different strains of mice and rats used as models for the 
evaluation of RA; among them the most representative strains are Lewis, DBA 1/J, C57BL/6, and K BxN, which respond 
to different genotypic and phenotypic characteristics.
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6. Future prospect
Animal models, as we have already commented, still are the strongest link to evaluate therapeu-
tic compounds, at least in autoimmune diseases, such as rheumatoid arthritis. In general, each 
model provides different information about the disease, and it is suggested that for more reli-
able results, the evaluated compounds have been tested in two different models to have a little 
more certainty of the effects generated by the molecules that are determined in each experiment.
Efforts are currently directed to find a model that can more accurately reproduce the symp-
toms and signs of RA taking the security of continuing to obtain reliable results. Another 
strategy is that the route of administration is as aggressive and invasive as possible but repro-
duces precise results, so other routes are being evaluated such as systemic to thus discontinue 
intra-articular injection.
These studies are carried out with the aim of using as few animals as possible and, in turn, 
with the least suffering, due to the techniques to inoculate the therapeutic agent to be evalu-
ated, in addition to the fact that the population decline does not interfere in the test results.
7. Conclusion
Despite decades of research to eradicate the disease, RA remains one of the most prevalent 
diseases within its scope and even with a well-defined and unknown etiology. Currently, 
animal models continue to be an effective and necessary tool for the generation of knowledge 
on most autoimmune diseases including RA. Currently the animal models are still the main 
link to understand how the immune system attacks its own components (cells or organs), as 
well as the evaluation of molecules with therapeutic objectives.
Animal models, inducible (CIA models, passive antibody, or streptococcal wall transfer) or 
spontaneous (knockout mice), have been shown to be useful in understanding unknown pro-
cesses. For spontaneous models, it is difficult to perceive the mechanism by which the disease 
in which the therapeutic compounds are evaluated is triggered. In the same way, no animal 
model shows all the characteristics of the disease and the route by which the therapeutic agent 
is introduced can generate variation in the results, so this information should be complementary 
with the evaluation of more routes of administration. It is envisaged that the generation of new 
molecular techniques will help to determine the complexity of the functioning of RA as well as 
to evaluate the different routes of administration of therapeutic compounds pending the attain-
ment of low toxicity and wide benefit therapies that are determined and used for clinical phases.
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